Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SLRX

SLRX - Salarius Pharmaceuticals Inc Stock Price, Fair Value and News

$0.83+0.03 (+3.75%)
Market Closed

80/100

SLRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

80/100

SLRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.36

Target 3M

$1.09

Target 6M

$1.23

SLRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SLRX Price Action

Last 7 days

-14.3%

Last 30 days

21.9%

Last 90 days

-80.2%

Trailing 12 Months

-98.1%

SLRX RSI Chart

SLRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SLRX Valuation

Market Cap

4.9M

Price/Earnings (Trailing)

-0.97

Price/Sales (Trailing)

2.99

EV/EBITDA

-0.02

Price/Free Cashflow

-1.1

SLRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.36

Target 3M

$1.09

Target 6M

$1.23

SLRX Fundamentals

SLRX Revenue

Revenue (TTM)

1.8M

SLRX Earnings

Earnings (TTM)

-5.0M

Earnings Growth (Yr)

10.15%

Earnings Growth (Qtr)

8.81%

SLRX Profitability

EBT Margin

-2025.02%

Return on Equity

-117.81%

Return on Assets

-82.09%

Free Cashflow Yield

-91.11%

SLRX Investor Care

Shares Dilution (1Y)

6001.53%

Diluted EPS (TTM)

-24.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20215.4M4.7M3.3M1.8M
20203.9M4.3M4.8M5.2M
20191.5M2.2M2.6M3.5M
20181.2M1.1M1.2M1.1M
20171.3M1.5M1.3M1.3M
2016171.8K268.3K852.7K1.1M
201522.5K36.0K43.8K72.0K
20140000
Get all data in R, Python etc through our Historical Stock Data APIs

About Salarius Pharmaceuticals Inc

SLRX
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
 CEO
 WEBSITEsalariuspharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES12

Salarius Pharmaceuticals Inc Frequently Asked Questions

SLRX is the stock ticker symbol of Salarius Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of Salarius Pharmaceuticals Inc is 4.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SLRX's fair value in chart for subscribers.

The fair value guage provides a quick view whether SLRX is over valued or under valued. Whether Salarius Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Salarius Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLRX.

As of Tue Jan 27 2026, SLRX's PE ratio (Price to Earnings) is -0.97 and Price to Sales (PS) ratio is 2.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLRX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Salarius Pharmaceuticals Inc has provided -0.746 (multiply by 100 for percentage) rate of return.